Pharmaceutical Executive March 6, 2024
Mike Hollan

Heavey discusses how the industry can avoid having efforts to accelerate discovery and development be hampered by manufacturing concerns.

For the pharmaceutical industry, the ability to produce drugs is just as important as the ability to develop new drugs. It doesn’t matter what drugs get developed if the industry can’t produce them to match the demand. Barry Heavey, supply chain lead at Accenture, spoke with Pharmaceutical Executive about how digital tools can help the manufacturing side keep up with the development side.

Pharmaceutical Executive: What would cause efforts to accelerate discovery and development to be hampered by clinical/commercial manufacturing?
Barry Heavey: New molecules moving quickly from discovery through clinical trial to launch may be difficult to manufacture at the pace required....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Interview / Q&A, Pharma, Pharma / Biotech, Supply Chain, Technology, Trends
Project Optimus: helping or hindering cancer drug development?
Faster Drug Discovery: Yseop & AWS Unveils GenAI Tool for Biopharma R&D
Quest to ramp up AI capabilities with purchase of PathAI’s diagnostic lab
Karius Secures $100M to Expand Non-Invasive Pathogen Blood Test
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold

Share This Article